Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2011, Issue , 2011, Pages 121-127

  Smith, Catherine C ^a   Shah, Neil P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; HUMAN; METABOLISM; REVIEW; TREATMENT OUTCOME;

DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84859375083     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2011.1.121     Document Type: Review

References (0)